BeiGene licenses CDK2 inhibitorCDK2 inhibitor from Ensem in potential $1.33B deal
2023-11-21
引进/卖出
BeiGene has struck a deal with Ensem Therapeutics to license an oral cyclin-dependent kinase 2 (CDK2) inhibitorcyclin-dependent kinase 2 (CDK2) inhibitor in exchange for an undisclosed upfront payment and up to $1.33 billion in milestones, the companies announced Tuesday.
Ensem will also get tiered royalties for handing over the exclusive global license to the drug, which the companies said is “Investigational New Drug (IND) application-ready” and Ensem’s most advanced candidate. While they didn’t name the program in the press release, Ensem’s website identifies the BeiGene-partnered program as ETX-197.
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-靶点
药物
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。